Joshua P. Plotnik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Joshua P. Plotnik has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Ryan A. McClure
Chan Zuckerberg Biohub, Chicago, Illinois 60642, United States
58 shared publications - Lloyd T. Lam
Precision Medicine, Translational Oncology, AbbVie Inc., North Chicago, Illinois. 3
48 shared publications - William N. Pappano
AbbVie Inc 1 N. Waukegan Rd. North Chicago Illinois
32 shared publications - Adam E. Richardson
AbbVie Inc 1 N. Waukegan Rd. North Chicago Illinois
31 shared publications - Anthony Mastracchio
AbbVie Inc 1 N. Waukegan Rd. North Chicago Illinois
31 shared publications - Ashley Wilson
Department of Lymphoma and Myeloma University of Texas MD Anderson Cancer Center Houston Texas
31 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
In vitro and in vivo combination of ABBV-MALT1 and venetoclax
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
In vitro and in vivo combination of ABBV-MALT1 and venetoclax
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Pan-lineage PRISM analysis of ABBV-MALT1 sensitivity.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Pan-lineage PRISM analysis of ABBV-MALT1 sensitivity.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary File 1 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Excel Workbook ABBV-MALT1 Pharmacology
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 1 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Excel Workbook ABBV-MALT1 Pharmacology
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
MALT1 and BCL2 inhibition do not antagonize each other in monotherapy sensitive patient derived xenografts
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
MALT1 and BCL2 inhibition do not antagonize each other in monotherapy sensitive patient derived xenografts
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary File 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary File 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary File 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma